Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NSAIDs use may cut breast cancer risk

This article was originally published in The Tan Sheet

Executive Summary

Non-steroidal anti-inflammatory drug use, including aspirin and ibuprofen, is associated with a reduced risk of breast cancer, according to a meta-analysis published Oct. 7 in the Journal of National Cancer Institute. The review of 38 studies conducted between January 1966 and July 2008 found women using NSAIDs were 12 percent less likely to develop breast cancer than women who did not. Ibuprofen use reduced the risk by 21 percent and aspirin use by 13 percent. The study did not find that higher doses or longer duration - especially of aspirin or ibuprofen - further reduced the risk of breast cancer. Researchers, led by Bahi Takkouche at the University of Santiago de Compostela in Spain, acknowledge weaknesses in the meta-analysis, including not considering other drugs participants took

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel